Roivant receives bad news — and so does Softbank

Last month, Softbank, through its massive Vision Fund, led the single biggest private financing round for a health care company ever, leading a $1.1 billion round in the drug holding outfit Roivant Sciences. Today, the Japanese conglomerate might be regretting that decision. The reason: despite hundreds of millions of dollars poured into one of Roivant’s publicly traded subsidiaries… Read More